Understanding Momentum Shifts in (ALDX)
Aldeyra Therapeutics Inc. (ALDX) is currently facing weak near and mid-term sentiment despite a strong long-term outlook, with support levels being tested. Institutional trading strategies identify a significant risk-reward setup targeting a 29.2% gain if the $5.30 support holds, while multi-timeframe analysis highlights key resistance at $6.85.
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
Aldeyra Therapeutics (ALDX) shares have seen a 0.6% gain recently, with Wall Street analysts projecting a potential upside of 79.3%, reaching a mean estimate of $9.00. While price targets can be misleading, the strong agreement among analysts and a 19.4% increase in the Zacks Consensus Estimate for current year earnings suggest a legitimate reason for optimism. ALDX currently holds a Zacks Rank #2 (Buy), indicating further potential upside in the near term.
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
Aldeyra Therapeutics (ALDX) shares have seen a recent gain, and Wall Street analysts project a potential upside of 79.3%, with a mean target of $9. This optimistic forecast is further supported by a strong consensus among analysts regarding higher earnings estimates, leading to a Zacks Rank #2 (Buy). While investors should be cautious with price targets, the agreement and improved earnings outlook suggest a positive short-term outlook for ALDX.
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The virtual chat is scheduled for February 25, 2026, at 10:40 a.m. ET and will be webcast live on Aldeyra's investor relations website. Aldeyra is a biotechnology company developing innovative therapies for immune-mediated diseases.
Aldeyra's Dry Eye Therapy Faces FDA In March - Will The Third Time Be A Charm?
Aldeyra Therapeutics' dry eye disease treatment, Reproxalap, is facing its third FDA decision in March 2026 after two previous rejections. The FDA extended the review deadline, citing the need for a full Clinical Study Report from a recent trial, despite the drug showing activity but not statistically significant improvement in symptoms. If approved, Aldeyra stands to receive significant milestone payments and profit sharing from AbbVie under their exclusive option agreement.
Aldeyra's Dry Eye Therapy Faces FDA In March - Will The Third Time Be A Charm?
Aldeyra Therapeutics' dry eye disease treatment, Reproxalap, is facing its third FDA decision in March 2026 after two previous rejections due to insufficient efficacy. The FDA extended the decision date to review a full Clinical Study Report, which showed the drug active but missing its primary endpoint for symptom improvement. If approved, Aldeyra stands to receive significant milestone payments and a profit-sharing agreement with AbbVie Inc.
Avoiding Lag: Real-Time Signals in (ALDX) Movement
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) shows weak near-term sentiment but strong mid and long-term outlooks, with a mid-channel oscillation pattern in play. An exceptional 165.0:1 risk-reward setup targets a 32.5% gain versus 0.2% risk, and positive sentiment is currently prevailing. The article provides detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for ALDX.
Wall Street analysts predict a 65.75% upside in Aldeyra Therapeutics (ALDX): Here's what you should know
This article discusses the optimistic outlook from Wall Street analysts for Aldeyra Therapeutics (ALDX), predicting a potential upside of 65.75%. It highlights the average broker recommendations, price targets, and the company's recent stock performance as key factors for this positive forecast. Investors are encouraged to consider these professional insights when evaluating ALDX.
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know
Wall Street analysts are predicting a significant upside of 65.75% for Aldeyra Therapeutics (ALDX) based on their short-term price targets, with the stock closing at $5.43 and a mean target of $9.00. While cautioning against relying solely on price targets, the article highlights strong agreement among analysts regarding the company's earnings prospects and a Zacks Rank #2 (Buy) as potential indicators of future growth. Investors are advised to view price targets with skepticism but consider the positive trend in earnings estimate revisions.
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design
Aldeyra Therapeutics (ALDX) saw its shares rise over 8% after the FDA endorsed the proposed trial design for its drug ADX-2191 in patients with proliferative vitreoretinopathy (PVR). The company plans to initiate the pivotal Phase 3 GUARD trial in the second half of 2024. ADX-2191 has already received Orphan Drug and Fast Track designations for PVR.
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX
PFG Investments LLC significantly cut its stake in Aldeyra Therapeutics (NASDAQ:ALDX) by 74.3% in Q3, selling 191,300 shares and retaining 66,000 shares valued at $345,000. Despite this reduction and mixed analyst ratings, Aldeyra Therapeutics beat Q3 EPS estimates and institutional investors collectively own 59.71% of the company's stock. The biotechnology company has a "Hold" consensus rating with a $9.50 price target.
Discipline and Rules-Based Execution in ALDX Response
This article analyzes Aldeyra Therapeutics Inc. (NASDAQ: ALDX), highlighting strong sentiment across all horizons and an exceptional 165.0:1 risk-reward setup targeting a 33.1% gain. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis. The report also offers access to real-time signals and institutional-grade analysis for subscribers.
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call
Aldeyra Therapeutics faces a critical FDA decision on March 16, 2026, for its dry eye drug reproxalap, which is central to the company's growth. The outcome will significantly impact its stock value, with a potential $100 million upfront payment and milestones from an AbbVie option agreement if approved. Despite high risk and volatility, analysts see substantial upside contingent on regulatory success for its lead asset.
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) after the company received a Complete Response Letter from the FDA for its New Drug Application for reproxalap, an investigational dry eye disease treatment. The FDA stated that the NDA "failed to demonstrate efficacy" and identified concerns with the submitted trial data, leading to a sharp drop in Aldeyra's stock price. The firm is encouraging investors to contact them to learn more about the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera
Bronstein, Gewirtz & Grossman, LLC is investigating Aldeyra Therapeutics, Inc. (ALDX) following a Complete Response Letter from the FDA regarding its dry eye disease drug, reproxalap. The FDA indicated that the New Drug Application (NDA) failed to demonstrate efficacy in adequate studies and requested an additional study. This news led to a sharp drop in Aldeyra's stock price, prompting the firm to encourage shareholders to join its investigation.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update
Aldeyra Therapeutics (NASDAQ:ALDX) saw a 20.1% decrease in short interest in December, with 4,951,552 shares shorted as of December 31st, representing 9.0% of the company's shares and a days-to-cover ratio of 3.0. The company's shares were trading up 5% at $4.63 with a market capitalization of $278.5 million; analysts have a "Hold" rating and a $9.50 target price. Institutional investors own 59.71% of the company, which reported Q3 EPS of -$0.13, beating estimates.
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners
Institutional investors with a 48% stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) are likely pleased with the recent 13% share price increase, which follows a 4.3% decline over the past year. The company's ownership structure shows that 14 top investors collectively hold 51% of the shares, while insiders own 2.4% and the general public makes up 31%. Private equity firms hold 18% of the company, influencing corporate strategy.
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate
The FDA has extended the review period for Aldeyra Therapeutics' dry eye drug candidate, reproxalap, moving the PDUFA deadline to March 16, 2026. This delay is due to the FDA requesting a complete Clinical Study Report from a field study which was classified as a "major amendment." The extension will allow the agency to evaluate conflicting trial outcomes, as the drug performed well in controlled studies but missed its primary endpoint in a field trial.
Behavioral Patterns of ALDX and Institutional Flows
This article from Stock Traders Daily analyzes Aldeyra Therapeutics Inc. (NASDAQ: ALDX) using AI models to generate trading strategies for different risk profiles. It highlights key findings and offers institutional-grade analysis, real-time signals, and risk management tools to subscribers. The article promotes accessing these features by creating a free account.
Aldeyra drops as FDA delays review of marketing application for lead drug
Aldeyra Therapeutics' stock dropped after the FDA issued a refuse-to-file letter regarding its new drug application for reproxalap, a treatment for dry eye disease. The FDA indicated that the submission was incomplete without additional clinical trial data, leading to a delay in the drug's potential approval and market entry. The company plans to meet with the FDA to address the deficiencies and resubmit the application.
Aldeyra drops as FDA delays review of marketing application for lead drug
Aldeyra Therapeutics' stock dropped significantly after the FDA informed the company of a major deficiency in its new drug application (NDA) for topical ocular reproxalap, a potential treatment for dry eye disease. This deficiency prevents the agency from completing its review in the current cycle, leading to an immediate 64% plunge in Aldeyra's shares. The company plans to request a Type A meeting with the FDA to discuss the issue.
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving Average - Time to Sell?
Aldeyra Therapeutics (NASDAQ:ALDX) stock recently fell below its 50-day moving average, trading at $4.18 against a 50-day average of $4.97, which is a bearish technical signal. Analysts currently have a "Hold" consensus rating with an average price target of $9.50. Institutional investors own about 59.7% of the company, with notable increases in holdings by firms like AQR Capital Management and Acadian Asset Management.
Aldeyra Therapeutics Announces Resignation of Chief Development Officer
Aldeyra Therapeutics, Inc. announced the resignation of Stephen G. Machatha, Ph.D., from his role as Chief Development Officer. Dr. Machatha will depart on or before March 31, 2026, to pursue other professional opportunities. This information was based on an SEC filing from the company.
Aldeyra Therapeutics chief development officer to step down by March 2026
Aldeyra Therapeutics announced that Stephen G. Machatha, Ph.D., its chief development officer, will resign by March 31, 2026, to pursue other professional opportunities. Dr. Machatha will assist with the transition and receive a lump sum payment, with the resignation not attributed to any disputes. The company also reported positive results for ADX-629 in treating alcohol-associated hepatitis and expanded its RASP modulator platform to include neuroinflammatory diseases.
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving Average - Time to Sell?
Aldeyra Therapeutics (NASDAQ:ALDX) saw its shares cross above its 50-day moving average during Wednesday trading, closing at $5.18 with a volume of 554,170 shares. Analysts currently have a "Hold" rating on the stock with a consensus target price of $9.50, despite the company posting a slight quarterly EPS beat. Institutional investors have been adjusting their stakes in ALDX, with a significant portion of the stock now held by these entities.
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman
Aldeyra Therapeutics, Inc. (ALDX) saw its stock plummet over 70% after the FDA issued a Complete Response Letter for its dry eye disease drug, reproxalap, citing a lack of demonstrated efficacy in adequate and controlled studies. This rejection, which wiped out over $200 million in market capitalization, has prompted Hagens Berman to launch an investigation into potential securities law violations, as the company had previously offered assurances of imminent approval. Investors who suffered substantial losses are encouraged to contact Hagens Berman for more information regarding the investigation.
Aldeyra Therapeutics chief development officer to step down by March 2026
Aldeyra Therapeutics' Chief Development Officer, Stephen G. Machatha, Ph.D., will resign by March 31, 2026, to pursue other opportunities. He will assist with the transition, continuing to receive his salary and benefits, and will get a lump sum payment of $88,000, with another $88,000 available upon executing a release of claims. The company, listed on Nasdaq under ALDX, stated the resignation was not due to any dispute with management or the board.
Aldeyra Therapeutics chief development officer to step down by March 2026
Aldeyra Therapeutics' Chief Development Officer, Stephen G. Machatha, Ph.D., will resign by March 31, 2026, to pursue other opportunities. He will assist with the transition and receive his current salary, benefits, and an $88,000 bonus payment, with a potential additional $88,000 upon executing a release of claims. The company clarified that his resignation is not due to disputes regarding operations or financial practices.
Aldeyra Therapeutics Announces Chief Development Officer Resignation
Aldeyra Therapeutics announced the voluntary resignation of Chief Development Officer Stephen G. Machatha, effective by March 31, 2026. Machatha will remain through a transition period, continuing to receive salary, benefits, and equity vesting, and is eligible for a bonus. His departure is not due to disagreements over operations or financial reporting, and an AI analyst rates ALDX stock as "Neutral" due to weak financial performance despite some clinical progress.
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
This article highlights three promising penny stocks—Aldeyra Therapeutics (ALDX), Cytek Biosciences (CTKB), and Dingdong (Cayman) (DDL)—that show potential for growth given the current positive momentum in broader markets. Aldeyra is a pre-revenue biotech firm with a focus on therapies for immune-mediated diseases, Cytek Biosciences provides cell analysis solutions, and Dingdong (Cayman) is a resilient e-commerce company in China. Each company's financial health, recent developments, and market capitalization are reviewed to suggest their investment potential despite the speculative nature of penny stocks.
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw its institutional shareholders benefit significantly from a 24% stock price gain last week, increasing their one-year returns to 3.5%. Institutions hold the largest stake at 48%, making them highly sensitive to stock movements. Key investors include Knoll Capital Management, holding 9.1%, with the top 14 shareholders collectively owning 51% of the company.
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap
Aldeyra Therapeutics announced that the FDA has extended the PDUFA date for its investigational drug, topical ocular reproxalap, for the treatment of dry eye disease. This extension impacts the review timeline but does not indicate the eventual outcome. The company has scheduled a conference call for December 16, 2025, to discuss this update, while also highlighting various risks and forward-looking statements regarding regulatory approval and commercial potential.
FDA Action Alert: GSK, Aldeyra, Rhythm and More
The FDA is poised to make seven significant drug decisions by the end of December, including approvals for rare obesity and inflammatory diseases. Key potential approvals include GSK's depemokimab for asthma and CRSwNP, Aldeyra's reproxalap for dry eye disease, and Rhythm Pharmaceuticals' Imcivree for acquired hypothalamic obesity. Also awaiting decisions are Vanda Pharmaceuticals' gastroparesis drug tradipitant after a public dispute, Corcept Therapeutics' relacorilant for Cushing's syndrome, and NRx Pharmaceuticals' NRX-101 for bipolar depression.
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug
The FDA has extended the PDUFA target action date for Aldeyra Therapeutics' (NASDAQ: ALDX) dry eye disease drug, reproxalap, to March 16, 2026. This extension follows Aldeyra's submission of a Clinical Study Report for a field trial, which the FDA considered a major amendment to the New Drug Application. Aldeyra's shares dropped following the announcement.
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?
Aldeyra Therapeutics' stock surged 31% after the FDA extended its review of the dry eye drug Reproxalap to March 16, 2026, without raising new issues. The extension was triggered by the FDA classifying a submitted Clinical Study Report as a major amendment. The FDA has also shared a draft label and indicated next steps, signaling continued regulatory progress.
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA
Aldeyra Therapeutics announced that the FDA has extended the PDUFA date for its drug reproxalap to March 16, 2026, requesting a Clinical Study Report for the NDA. The original field trial for reproxalap did not meet its primary endpoint. The FDA also plans to discuss labeling by February 16, 2026.
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026
Aldeyra Therapeutics announced that the FDA has extended the PDUFA target action date for their reproxalap New Drug Application (NDA) for dry eye disease to March 16, 2026. This extension follows the FDA's request for the Clinical Study Report for a dry eye disease field trial, which, despite supporting reproxalap's activity, did not meet its primary endpoint. Aldeyra plans to host a conference call to discuss this development.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Pomerantz LLP has initiated an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) following a significant stock drop. This investigation comes after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter, indicating that Aldeyra's New Drug Application for reproxalap for dry eye disease failed to demonstrate efficacy in adequate and well-controlled studies. Investors are encouraged to contact Pomerantz LLP regarding potential securities fraud claims.
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX
683 Capital Management LLC significantly increased its stake in Aldeyra Therapeutics (NASDAQ:ALDX) by 126.9% in the second quarter, now holding 1,080,000 shares valued at approximately $4.14 million. The biotechnology company, specializing in immune-mediated diseases, has a "Hold" consensus rating from analysts with an average price target of $9.50. Aldeyra recently reported Q3 earnings of ($0.13) EPS, surpassing estimates.
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) recently experienced a 10% stock pullback, adding to its one-year losses. Institutional investors, who hold a 48% stake in the company, were significantly impacted and may consider selling their shares if the stock weakness continues. The company's largest shareholder is Knoll Capital Management with 9.1%, and insiders collectively own US$8.9 million worth of shares.
Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX
Kennondale Capital Management LLC significantly reduced its stake in Aldeyra Therapeutics, Inc. by selling 94,551 shares, trimming its position by 62.5%. Despite this, other institutions like Invesco Ltd. dramatically increased their holdings, leading to institutional investors owning 59.71% of the company's stock. Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $316.46 million, a negative PE ratio, and analysts have an average "Hold" rating with a target price of $9.50.
Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap
Aldeyra Therapeutics has expanded its RASP platform to include central nervous system diseases, driven by preclinical results for ADX-248 in neuroinflammatory conditions like Parkinson's and ALS. Furthermore, the FDA concluded inspections of reproxalap manufacturing sites without needing further action, and manufacturing updates for reproxalap were provided during a webcast.
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Aldeyra Therapeutics announced that President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on November 20, 2025, at 11:30 a.m. GMT. The discussion with Clara Dong, Ph.D., Vice President, Biotechnology Equity Research at Jefferies LLC, will be webcast live and archived for 90 days on the Aldeyra website. The company focuses on developing innovative therapies for immune-mediated diseases by modulating protein systems.
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Aldeyra Therapeutics announced positive Phase 2 clinical trial results for ADX-629 in alcohol-associated hepatitis, showing significant improvement in liver function. Following these findings, the company is re-focusing its RASP modulator pipeline on next-generation molecules ADX-248 and ADX-246 for various immune-mediated diseases, extending its cash runway into the second half of 2027. This strategic shift aims to develop novel therapeutics prudently while maintaining growth alongside existing pre-commercial programs.
Aldeyra reshuffles pipeline, culling asset despite Phase II success
Aldeyra Therapeutics has decided to discontinue the development of its Phase II asset, ADX-629, despite positive results in alcohol-associated hepatitis where it significantly improved hepatic function and inflammation markers. The company is reprioritizing its pipeline to focus on two next-generation RASP modulators, ADX-248 and ADX-246, with IND filings anticipated in 2026 for immune-mediated diseases, metabolic inflammation, and dry age-related macular degeneration. This strategic shift has extended Aldeyra's operational runway into the second half of 2027 and follows previous setbacks for its dry eye drug reproxalap.
Dry Eye Disease Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight
DelveInsight's Dry Eye Disease Pipeline Drugs Insights Report 2025 details a robust pipeline with over 50 active players and 60+ therapies in development for Dry Eye Disease (DED) treatment. The report highlights key clinical trial advancements from companies like Hoffmann-La Roche, Dompé Farmaceutici S.p.A, and Aldeyra Therapeutics Inc., and profiles promising emerging drugs. It also provides an overview of DED, current therapeutic assessments, and future market perspectives.
Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade)
Aldeyra (ALDX) is downgraded to Hold due to high risk surrounding reproxalap's December PDUFA for dry eye disease, following two FDA Complete Response Letters and mixed trial results which cast doubt on symptom efficacy. Significant financial risks persist, especially if AbbVie declines its co-license option, given Aldeyra's limited cash and the high costs associated with product launch. The unpredictable regulatory landscape and microcap risks warrant extreme caution, making limited allocation suitable only for highly risk-tolerant investors awaiting post-PDUFA clarity.
High Growth Tech Stocks To Watch In US August 2025
This article highlights top high-growth tech stocks in the US for August 2025, despite the broader market's mixed performance. It details ten companies with strong revenue and earnings growth, including Aldeyra Therapeutics, TaskUs, and Olo, providing an overview of their operations and financial forecasts. The report also advises investors on how to utilize Simply Wall St's tools for further analysis of these growth opportunities.
ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites
ADX-2191, a novel methotrexate formulation developed by Aldeyra Therapeutics, has received orphan designation from the European Medicines Agency (EMA) for large B-cell lymphoma (LBCL) of immune-privileged sites, including primary vitreoretinal lymphoma (PVRL). This designation complements a similar one from the FDA. The drug is designed as a vitreous-compatible intravitreal injection for rare retinal diseases, and while an FDA complete response letter was issued previously due to insufficient efficacy data for PVRL, ADX-2191 has also gained fast track designation for retinitis pigmentosa.
Don't Ignore The Insider Selling In Aldeyra Therapeutics
Aldeyra Therapeutics's Chief Development Officer recently sold US$114k worth of shares, representing 12% of his holding. This was the largest insider sale in the past year, and while insider selling can be a weak signal, repeated sales below the current price suggest insiders view a lower price as reasonable. The article notes that insider ownership in the company is relatively low, which, combined with the selling activity, suggests caution for potential investors.
